To test this hypothesis, we applied a novel high-resolution and high-throughput comparative screening pipeline (serum antibody repertoire analysis, SARA) [paper in preparation] to anti-TIF1 autoantibody-positive dermatomyositis patients (DM) and matched healthy control (HC) plasma. Here, TRIM24 is linked to dermatomyositis.